QQQ   308.76 (-0.69%)
AAPL   158.15 (-1.31%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.15 (-1.31%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.15 (-1.31%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
QQQ   308.76 (-0.69%)
AAPL   158.15 (-1.31%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:XERS

Xeris Biopharma - XERS Stock Forecast, Price & News

$1.27
-0.01 (-0.78%)
(As of 03/27/2023 04:00 PM ET)
Add
Compare
Today's Range
$1.26
▼
$1.31
50-Day Range
$1.13
▼
$1.53
52-Week Range
$0.97
▼
$2.85
Volume
309,383 shs
Average Volume
1.14 million shs
Market Capitalization
$172.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.38

Xeris Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
319.9% Upside
$5.38 Price Target
Short Interest
Bearish
6.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
0.43mentions of Xeris Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.56) to ($0.33) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

See Top Rated MarketRank™ Stocks Here

XERS stock logo

About Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Stock News Headlines

March 10, 2023 | proactiveinvestors.com
Xeris Biopharma shares 2023 financial guidance after positive year end and fourth quarter results
March 9, 2023 | finance.yahoo.com
Q4 2022 Xeris Biopharma Holdings Inc Earnings Call
March 27, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 8, 2023 | msn.com
Xeris stock falls ~10% despite revenue growth, narrowed loss in Q4
March 8, 2023 | finance.yahoo.com
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
February 23, 2023 | finance.yahoo.com
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023
February 2, 2023 | finance.yahoo.com
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
January 30, 2023 | proactiveinvestors.com
Xeris Biopharma sees FDA grant Orphan-drug exclusivity to Recorlev for treatment of Cushing's syndrome
March 27, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
January 30, 2023 | marketwatch.com
Xeris Biopharma Gets Orphan-Drug Exclusivity for Recorlev
January 30, 2023 | markets.businessinsider.com
FDA Grants Orphan-drug Exclusivity For Xeris' Recorlev For Endogenous Cushing's Syndrome Treatment
January 30, 2023 | msn.com
Xeris stock rises on FDA orphan drug status for hormone disorder therapy Recorlev
January 30, 2023 | finance.yahoo.com
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
January 5, 2023 | finance.yahoo.com
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
January 5, 2023 | finance.yahoo.com
Xeris Biopharma Updates Its Outlook For 2022
December 31, 2022 | finance.yahoo.com
A Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider increased their holdings by 16% last year
December 18, 2022 | proactiveinvestors.com
Xeris Biopharma breaks down end of year collaboration and dose-finding study updates
December 15, 2022 | proactiveinvestors.com
Xeris Biopharma to proceed with Phase II study of levothyroxine for hypothyroidism
December 15, 2022 | finance.yahoo.com
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
November 28, 2022 | nasdaq.com
New Research Partnership With Horizon Therapeutics Could Be The Next Revenue Catalyst For Xeris
November 23, 2022 | proactiveinvestors.com
Xeris Biopharma inks research collaboration and option agreement with Horizon Therapeutics
November 23, 2022 | finance.yahoo.com
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
November 16, 2022 | finance.yahoo.com
Individual investors account for 51% of Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) ownership, while institutions account for 37%
November 14, 2022 | markets.businessinsider.com
SVB Securities Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)
November 11, 2022 | proactiveinvestors.com
Xeris Biopharma posts record 3Q revenue as more patients utilize its treatments
November 9, 2022 | apnews.com
Xeris Biopharma: Q3 Earnings Snapshot
November 9, 2022 | seekingalpha.com
Xeris Biopharma Holdings, Inc. (XERS) Q3 2022 Earnings Call Transcript
See More Headlines
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Company Calendar

Last Earnings
11/09/2021
Today
3/27/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XERS
CUSIP
N/A
CIK
1867096
Web
www.xerispharma.com
Phone
(844) 445-5704
Fax
N/A
Employees
294
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.38
High Stock Price Forecast
$6.50
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+311.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-94,660,000.00
Net Margins
-85.86%
Pretax Margin
-87.15%
Return on Equity
-135.91%
Return on Assets
-28.21%

Debt

Debt-to-Equity Ratio
4.14
Current Ratio
2.54
Quick Ratio
2.20

Sales & Book Value

Annual Sales
$110.25 million
Price / Sales
1.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.33 per share
Price / Book
3.95

Miscellaneous

Outstanding Shares
135,530,000
Free Float
128,524,000
Market Cap
$176.87 million
Optionable
Not Optionable
Beta
N/A

Social Links


Key Executives

  • Paul R. EdickPaul R. Edick
    Chairman & Chief Executive Officer
  • John Patrick Shannon
    President & Chief Operating Officer
  • Steven M. Pieper
    Chief Financial Officer
  • Steven Prestrelski
    Chief Scientific Officer
  • Ken Johnson
    Senior VP-Clinical Development & Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













XERS Stock - Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XERS shares.
View XERS analyst ratings or view top-rated stocks.

What is Xeris Biopharma's stock price forecast for 2023?

4 brokerages have issued 12-month price targets for Xeris Biopharma's stock. Their XERS share price forecasts range from $4.00 to $6.50. On average, they anticipate the company's stock price to reach $5.38 in the next year. This suggests a possible upside of 311.9% from the stock's current price.
View analysts price targets for XERS or view top-rated stocks among Wall Street analysts.

How have XERS shares performed in 2023?

Xeris Biopharma's stock was trading at $1.33 at the start of the year. Since then, XERS stock has decreased by 1.9% and is now trading at $1.3050.
View the best growth stocks for 2023 here.

Are investors shorting Xeris Biopharma?

Xeris Biopharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 8,280,000 shares, an increase of 20.9% from the February 28th total of 6,850,000 shares. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is currently 7.6 days.
View Xeris Biopharma's Short Interest.

When is Xeris Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our XERS earnings forecast.

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. The firm earned $11.04 million during the quarter, compared to the consensus estimate of $10.43 million. Xeris Biopharma had a negative net margin of 85.86% and a negative trailing twelve-month return on equity of 135.91%. During the same period in the prior year, the firm posted ($0.35) earnings per share.

What ETF holds Xeris Biopharma's stock ?

iShares Neuroscience and Healthcare ETF holds 18,168 shares of XERS stock, representing 0.49% of its portfolio.

What guidance has Xeris Biopharma issued on next quarter's earnings?

Xeris Biopharma updated its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$165.00 million, compared to the consensus revenue estimate of $152.31 million.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI).

When did Xeris Biopharma IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Biopharma's stock symbol?

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.26%), Geode Capital Management LLC (1.79%), Millennium Management LLC (0.51%), Renaissance Technologies LLC (0.37%), Deltec Asset Management LLC (0.27%) and Charles Schwab Investment Management Inc. (0.26%). Insiders that own company stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends.

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xeris Biopharma's stock price today?

One share of XERS stock can currently be purchased for approximately $1.31.

How much money does Xeris Biopharma make?

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $176.87 million and generates $110.25 million in revenue each year. The company earns $-94,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Xeris Biopharma have?

The company employs 294 workers across the globe.

How can I contact Xeris Biopharma?

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.

This page (NASDAQ:XERS) was last updated on 3/27/2023 by MarketBeat.com Staff